Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

WOODLANDS SPECIALTY HOSPITAL

NPI: 1184042822 · THE WOODLANDS, TX 77386 · Occupational Therapist · NPI assigned 03/31/2014

$17K
Total Medicaid Paid
75
Total Claims
74
Beneficiaries
4
Codes Billed
2021-05
First Month
2023-09
Last Month

Provider Details

Authorized OfficialMOPARTY, RAVI (OWNER / CEO)
NPI Enumeration Date03/31/2014

Related Entities

Other providers sharing the same authorized official: MOPARTY, RAVI

ProviderCityStateTotal Paid
NORTH HOUSTON FAMILY MEDICINE PLLC SPRING TX $177K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 61 $487.17
2023 14 $16K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99284 Emergency department visit for the evaluation and management, high severity 14 13 $16K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 14 14 $437.46
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 34 34 $49.71
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 13 13 $0.00